...
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation.
【24h】

Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineation.

机译:分化型甲状腺癌放疗后复发的模式:对靶标体积的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Post-operative residual disease in differentiated thyroid cancer is an indication for external beam radiotherapy (EBRT) especially if there is poor radioiodine uptake by the residual disease. There are no standardized guidelines or consensus in target delineation for radiotherapy in thyroid cancer. AIMS: To determine the pattern of recurrence in patients with well differentiated thyroid cancer who received adjuvant or definitive radiotherapy as well as radioiodine ablation following surgery or biopsy with a view to better defining future target volume delineation for radiotherapy. MATERIALS AND METHODS: Forty-nine patients with differentiated thyroid cancer received radical external beam radiotherapy and radioiodine ablation (3.5GBq) following thyroidectomy or biopsy between 1990 and 2000. Nineteen patients had macroscopic residual (11) or inoperable disease (8), whilst 30 patients had clear (5) or microscopic positive resection margin (24), and 1 patient the resection margin status was unknown. All the patients were deemed high risk for local recurrence or progressive disease. The thyroid bed and regional nodes were irradiated using two radiotherapy techniques: (1) non co-planar lateral fields (NCLF) in coronal plane using 6MV photons to a dose of 45-50Gy in 16 fractions over 22 days and (2) anterior-posterior parallel pair of 6MV photons to a dose of 40-42.5Gy in 16 fractions over 22 days. There was no attempt to irradiate the lymph nodes in that part of the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina. RESULTS: The median follow-up was 5.4 years (range 0.9-12.4 years). The actuarial 5-year cause-specific survival and local control for the whole group was 75.7% and 81.4%, respectively. Of the 4 patients with mediastinal recurrence, all had neck recurrences and two had distant metastases. All the medisastinal recurrences occurred in superior mediastinum (level VII) and all were treated with NCLF in coronal plane radiotherapy technique. Furthermore, mediastinal recurrences did not occur in isolation. The 5-years loco-regional control rate was 89.1% for those with clear or microscopic positive margins and 69.2% for those with macroscopic residual or inoperable disease. Five-year cause specific survival was 58.3% for patients with macroscopic residual or inoperable disease and 91.4% for those with clear or microscopic positive margins. CONCLUSION: The status of postoperative margin relating to bulk of disease influences local control and cause specific survival. Surgical resection in locally advanced thyroid cancer should be performed by an experienced surgeon to achieve macroscopic clearance where possible. The majority of recurrences were loco-regional. The few superior mediastinal recurrences did not occur in isolation. All the mediastinal recurrences occurred in the superior mediastinum (level VII). We recommend the target volume should encompass the thyroid bed and regional neck nodes and the superior mediastinum level VII excluding the lymph nodes on both sides of the trachea within the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina (compartment 4). Thus, this should facilitate dose escalation to improve loco-regional control and avoiding radiation induced mediastinal toxicity.
机译:引言:分化型甲状腺癌的术后残留疾病是外部放射线疗法(EBRT)的适应症,尤其是如果残留疾病对放射性碘的吸收较差的话。甲状腺癌放疗的靶标确定尚无标准化指南或共识。目的:确定在接受手术或活检后接受辅助或确定性放疗以及放射碘消融的高分化甲状腺癌患者中的复发模式,以便更好地确定放射治疗的未来目标体积。材料与方法:1990年至2000年之间,有49例分化型甲状腺癌患者在进行了甲状腺切除术或活检后接受了根治性外照射和放射碘消融(3.5GBq)。19例患者有肉眼可见的残留(11)或不能手术的疾病(8),而30例有宏观残留患者有明确的切除切缘(5)或镜下阳性切缘(24),还有1例患者的切缘状态未知。所有患者均被认为具有局部复发或进行性疾病的高风险。使用两种放疗技术对甲状腺床和区域淋巴结进行照射:(1)在22天的时间内,使用6MV光子在冠状平面上的非共面侧向场(NCLF)照射16次,剂量为45-50Gy,(2)在22天内分16个部分将6MV光子的后平行平行对以40-42.5Gy的剂量照射。没有尝试照射从头颅静脉到隆突的前纵后纵隔部分的淋巴结。结果:中位随访时间为5.4年(范围0.9-12.4年)。整个组的5年特定原因的精算生存率和局部控制率分别为75.7%和81.4%。在4例纵隔复发患者中,所有人均患有颈部复发,其中2例具有远处转移。所有的纵隔复发都发生在纵隔上段(VII级),并且所有冠状动脉平面放疗均接受了NCLF治疗。此外,纵隔复发并不是孤立发生的。具有明确或微观阳性切缘的患者的5年局部区域控制率为89.1%,具有宏观残留或无法手术的患者的5年局部区域控制率为69.2%。具有宏观残留或无法手术疾病的患者的五年病因特异性存活率为58.3%,具有清晰或微观阳性切缘的患者为51.4%。结论:与大部分疾病有关的术后切缘状态影响局部控制并导致特定的生存。局部晚期甲状腺癌的手术切除应由经验丰富的医生进行,以在可能的情况下达到宏观清除率。多数复发是局部性的。少数上纵隔复发不是孤立发生的。所有纵隔复发均发生在上纵隔(VII级)。我们建议目标体积应包括甲状腺床和颈部区域淋巴结以及上纵隔VII级,但不包括从前臂后静脉延伸至隆突的前,后纵隔气管两侧的淋巴结(隔室4)。因此,这应有助于剂量增加,以改善局部区域控制并避免辐射引起的纵隔毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号